Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited announced that it received approval from the Belberry Human Research Ethics Committee in Australia to commence its First-in-Human Phase 1 clinical study of 177Lu-labeled RAD 202 for treating HER2-expressing solid tumors. This milestone is significant for the company as it advances its product pipeline and positions itself competitively in the oncology therapeutics market. The approval and subsequent study could potentially enhance the company’s market position and stakeholder interest, reflecting an important step in its operational and strategic objectives.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development of radiopharmaceuticals for cancer treatment. The company is involved in creating diagnostic and therapeutic products aimed at improving cancer patient outcomes.
YTD Price Performance: 16.67%
Average Trading Volume: 9,715,595
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$61.62M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.
